Mafei Kang

Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial

Ying Cheng, Yun Fan, Yanqiu Zhao et al. · Journal of Thoracic Oncology · 2024 · 132 citations · Full text

Medicine, Oncology, Pharmacology +4

First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial

Lin Shen, Yanqiao Zhang, Ziyu Li et al. · Nature Medicine · 2025 · 81 citations

Medicine, Oncology, Pharmacology +11

Sox12 Is a Cancer Stem-Like Cell Marker in Hepatocellular Carcinoma.

Song Zou, Chen Wang, Jiansheng Liu et al. · PubMed · 2017 · 36 citations · Full text

Medicine, Cancer Biology, Oncology +17

LncRNA DGCR5 regulates the non‐small cell lung cancer cell growth, migration, and invasion through regulating miR‐211‐5p/EPHB6 axis

Mafei Kang, Jieqiong Shi, Bihui Li et al. · BioFactors · 2019 · 31 citations

Medicine, Molecular Biology, Oncology +15

miR-33a inhibits cell proliferation and invasion by targeting CAND1 in lung cancer

Mafei Kang, Y. Li, Ying Zhao et al. · Clinical & Translational Oncology · 2017 · 30 citations

Medicine, Molecular Biology, Oncology +14